Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis

The study evaluates efficacy and safety of recombinant human parathyroid hormone (1–34) [rhPTH (1–34)] and alendronate (ALN) in the treatment of postmenopausal osteoporosis. Totally 65 postmenopausal women with osteoporosis were divided into 2 groups. PTH group received daily subcutaneous injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jing, Feng, Zhengping, Li, Yue, Pan, Tingting, Li, Qifu, Zhao, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392772/
https://www.ncbi.nlm.nih.gov/pubmed/30461654
http://dx.doi.org/10.1097/MD.0000000000013341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392772/
https://www.ncbi.nlm.nih.gov/pubmed/30461654
http://dx.doi.org/10.1097/MD.0000000000013341

Ejemplares similares